Over 25 Companies To Present At Emerald Groundhog Day Investment Forum

Emerald Asset Management will hold the 20 th Anniversary Emerald Groundhog Day Investment Forum on Thursday, February 7, 2013 at the Radisson Plaza-Warwick Hotel in Philadelphia . “Insight, information, energy and passion are the hallmarks of the Emerald Groundhog Day Investment Forum,” said Emerald Founder and CEO, Joseph E. Besecker. “The Forum provides a venue to discuss key challenges and opportunities confronting investors, corporate executives, and elected officials, including the ongoing spending and tax policy battles in Washington, questions about the sustainability of equity market gains and historically low fixed income interest rates, and the opportunities associated with the revitalization of the industrial sector and the rapid pace of technological innovation,” added Mr. Besecker.

The Forum will showcase investment opportunities in some of the Mid-Atlantic region’s fastest growing companies, as well as industry leaders from across the country. Senior management teams from twenty-six public and private companies are scheduled to make formal presentations during concurrent sessions. The Emerald Groundhog Day Investment Forum provides a unique opportunity for portfolio managers, analysts, and investment industry professionals to interact with senior executives representing a wide array of industries. In addition, analysts from Emerald will be sharing their views on the most compelling growth opportunities for the coming year. U.S. Senator Robert Casey, Jr. (Pennsylvania) is scheduled to present the event’s keynote address.

The Twentieth Annual Emerald Groundhog Day Investment Forum will also feature the thirteenth annual presentation of the “E-3” Awards. The E-3 (Emerald, Entrepreneurial and Excellence) Award presentations will recognize corporate leaders from both the public and private company sectors who exemplify entrepreneurial spirit and a commitment to excellence.

Presented by Emerald Asset Management, Forum sponsors include Pepper Hamilton LLP, Janney Capital Markets, Boenning & Scattergood, Greentree, Trout, Ebersole & Groff LLP, Sturdivant & Co., Patriot Financial Partners L.P. and Susquehanna International Group, LLP.

If you liked this article you might like

Alnylam Shares Skyrocket on Clinical Study Results - Biotech Movers

Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers

Tesla's Rally Has Died: Stock Falls to Sixth Worst Performer in Russell 1000

Biotech Movers: Inovio, Neurocrine, Alnylam

Biotech Movers: Ionis, Alnylam, Amicus, Minerva